Filter
697
Text search:
candidates
Featured
65
172
Language
Document type
347
139
84
34
32
25
12
10
6
4
3
1
Countries / Regions
45
28
18
17
16
16
14
12
12
12
11
11
11
10
10
9
9
9
8
8
8
8
7
7
6
6
6
6
5
5
5
5
5
5
4
4
4
4
4
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
256
54
28
25
21
8
4
1
Toolboxes
111
40
39
35
32
27
24
18
16
13
12
9
9
8
8
7
7
6
6
6
4
4
4
3
3
This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
Vaccines are supported by decades of medical research.
...
Cet article fait partie d’une série d’explications à propos de la mise au point et de la distribution des vaccins.
Available in different languages
Many countries are using the approach of mixing vaccine doses from different manufacturers. What do we know about the safety and efficacy of this approach? What does the evidence tell us about using a fraction of the vaccine dose ? Dr Katherine O’Brien explains in Science in 5 this week.
Closed C
...
As of January 20, 2021 the Covid-19 - living NMA initiative collected 150 RCTs and 36 non-randomised studies of vaccines from the ICTRP. 93 of these trials are recruiting patients.
These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenc
...
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto
...
orientations provisoires, première publication: 10 février 2021, mise à jour : 21 avril 2021, dernière mise à jour : 30 juillet 2021
временное руководство. Первый выпуск: 10 февраля 2021 г. Обновлено: 21 апреля 2021 г. Последнее обновление 30 июля 2021г.
This quick guide offers basic information about COVID-19, the Sinovac-CoronaVac COVID-19 vaccine and what to
expect following vaccination: ...
Cet article fait partie d’une série d’explications à propos de la mise au point et de la distribution des vaccins.
Available in English, French, Spanisch, Arabic, Chinese and Russian
How COVID-19 mRNA Vaccines Work
recommended
COVID-19 mRNA vaccines deliver directions to make a protein that educates our immune system, so it will neutralize the virus in future encounters. The mRNA-containing lipid particles are taken up by specialized immune system cells
COVID-19 Vaccine Resource Center
recommended
A collection of resources on Covid-19 vaccines, including frequently asked questions, continuing medical education, published research, and commentary.
COVAXINTM, India's indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) h
...
COVID-19 vaccine market dashboard
recommended
An interactive tool for partners, manufacturers, and countries to follow the developments of the COVID-19 vaccine market with up-to-date information.
As the designated COVAX procurement coordinator and procurement agent, UNICEF has launched the COVID-19 Vaccine Market Dashboard – an interactive
...
